Načítá se...
Cardiovascular Outcomes in Trials of New Antidiabetic Drug Classes
Type 2 diabetes is among the most prevalent chronic diseases worldwide and the prevention of associated cardiovascular complications is an important treatment goal. Sodium–glucose co-transporter 2 (SGLT2) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and dipeptidyl peptidase-4 (DPP-4...
Uloženo v:
| Vydáno v: | Card Fail Rev |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Radcliffe Cardiology
2021
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7970669/ https://ncbi.nlm.nih.gov/pubmed/33747548 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.15420/cfr.2020.19 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|